The Mammalian 43-kD Acetylcholine Receptor-associated Protein (RAPsyn) is Expressed in Some Nonmuscle Cells

Linda S. Musil, Donald E. Frail, and John P. Merlie
Department of Pharmacology, Washington University School of Medicine, St. Louis, Missouri 63110

Abstract. Torpedo electric organ and vertebrate neuromuscular junctions contain the receptor-associated protein of the synapse (RAPsyn) (previously referred to as the 43K protein), a nonactin, 43,000-Mr peripheral membrane protein associated with the cytoplasmic face of postsynaptic membranes at areas of high nicotinic acetylcholine receptor (AChR) density. Although not directly demonstrated, several lines of evidence suggest that RAPsyn is involved in the synthesis and/or maintenance of such AChR clusters. Microscopic and biochemical studies had previously indicated that RAPsyn expression is restricted to differentiated, AChR-synthesizing cells. Our recent finding that RAPsyn is also produced in undifferentiated myocytes (Frail, D. E., L. S. Musil, A. Bonanno, and J. P. Merlie. 1989. Neuron. 2:1077-1086) led us to examine whether RAPsyn is synthesized in cell types that never express AChR (i.e., cells of other than skeletal muscle origin). Various primary and established rodent cell lines were metabolically labeled with [3S]methionine, and extracts were immunoprecipitated with a monospecific anti-RAPsyn serum. Analysis of these immunoprecipitates by SDS-PAGE revealed detectable RAPsyn synthesis in some (notably fibroblast and Leydig tumor cell lines and primary cardiac cells) but not all (hepatocyte- and lymphocyte-derived) cell types. These results were further substantiated by peptide mapping studies of RAPsyn immunoprecipitated from different cells and quantitation of RAPsyn-encoding mRNA levels in mouse tissues. RAPsyn synthesized in both muscle and nonmuscle cells was shown to be tightly associated with membranes. These findings demonstrate that RAPsyn is not specific to skeletal muscle-derived cells and imply that it may function in a capacity either in addition to or instead of AChR clustering.

The nicotinic acetylcholine receptor (AChR) is concentrated on postsynaptic membranes of Torpedo electric organ and vertebrate neuromuscular junctions in remarkably high density clusters (3). Tightly associated with the cytoplasmic membrane face at these clusters is a nonactin 43,000-Mr peripheral membrane protein first referred to as simply 43K protein (20, 32, 33, 35, 45). Several indirect lines of evidence suggest that 43K protein may be involved in the establishment and/or maintenance of AChR clusters. First, immunofluorescence microscopy studies have demonstrated that 43K protein is detectable only directly under AChR clusters (21, 34) and accumulates at developing nerve-muscle synapses at the same rate as the AChR (10). In addition, 43K protein is in close enough physical proximity to the AChR that it can be chemically cross-linked to its β subunit in isolated Torpedo postsynaptic membranes, raising the possibility that these molecules interact with each other in the intact membrane (11). Extraction of 43K protein from Torpedo electric organ (2, 14, 40) or vertebrate skeletal muscle (5) membranes by treatment with alkaline solutions (pH > 11) does not affect the acetylcholine-activated permeability characteristics of the AChR (32), but markedly increases both the lateral (2, 5, 14) and rotational (40) mobility of the receptor in the plane of the plasma membrane. In contrast, removal of other cytoplasmic structural proteins associated with areas of AChR/43K protein clusters, such as vinculin, leaves AChR organization unaltered (6). We have given 43K protein the descriptive name of RAPsyn (receptor-associated protein of the synapse) (18) to reflect the close physical and potential functional relationship between it and the AChR suggested by these findings.

The temporal and spatial coexpression of RAPsyn and the AChR at the neuromuscular junction suggested to us that the synthesis of RAPsyn might be coordinate regulated with that of the AChR and other differentiated muscle-specific proteins (29). We were therefore surprised to find that RAPsyn is synthesized in undifferentiated myoblasts as well (19). Examination of key properties of RAPsyn, including membrane association, degradation rate, and labeling with [3H]myristate, revealed that RAPsyn expression is quantitatively and qualitatively similar in differentiated and undifferentiated...
cells (19). The presence of RAPsyn in the absence of AChR production led us to ask whether RAPsyn is also synthesized in cell types that never produce AChR (i.e., in cells of other than skeletal muscle origin). We report here that RAPsyn is synthesized in some, but not all, nonmuscle cells. RAPsyn may therefore serve some function in addition to or instead of AChR clustering.

Materials and Methods

Immunological Reagents

The production and characterization of the rabbit polyclonal anti-RAPsyn serum has been described previously (31). Total AChR α subunit was detected with the rat monoclonal antibody mAb61 which is specific for the α subunit and has been characterized by Tzartos et al. (46) and Merlie and Lindstrom (28).

Cell Culture

The clonal mouse muscle cell lines BC3H-1 (41) and C2 (48) were cultured as described (9, 28). 7-d-old differentiated cultures were used for all experiments. MA-10 cells, a clonal strain of mouse Leydig tumor cells, were grown as described by Ascoli (1). L929 fibroblasts were cultured in DME with 10% FBS. P815 mastocytoma cells and EL4 thymoma cells were maintained in RPMI supplemented with 10% bovine calf serum. All media contained penicillin G and gentamycin. Skeletal muscle cells were dissociated from the forelimbs of 20-d-old embryonic rats and cultured as described (26). Primary heart cell cultures were prepared from 1-d-old rat hearts (atria + ventricles) according to the method of Simpson and Savion and consisted of 75–80% myocytes as defined by beating and morphology (43). After 2 d in culture, the cell medium was switched to DME containing 10% FBS. Heart cells were used 5 d after plating.

Metabolic Labeling of Cells

To label adherent cells with [35S]methionine, cultures were washed twice with warmed DME without methionine. 2 ml of labeling medium (methionine-free DME with 5% dialyzed FCS, 20 μM methionine, and 0.2 mM of [35S]methionine) was added, and the plate was incubated for the times indicated in the individual experiments. Cell lines grown in suspension culture (P815, EL4) were pelleted by centrifugation at 600 g for 5 min at 4°C and washed twice with methionine-free medium before incubation with labeling medium (6 × 106 cells/ml). To assess the amount of protein synthesized during metabolic labeling of cells, an aliquot of labeled cell lysate was precipitated on Whatman disks with boiling 5% TCA. The disks were washed with 5% TCA at 4°C and washed twice with methionine-free medium before incubation with labeling medium (6 × 106 cells/ml). The cells were lysed with 5% TCA at 4°C followed by 95% ethanol, dried, and counted in a scintillation counter.

Preparation of Cell Lysates and Immunoprecipitations

At the end of the labeling period, medium was removed and cultures were rinsed three times with PBS followed by a single wash with extraction buffer (0.05 M NaCl, 0.01 M Heps, 2.5 mM MgCl2, 0.3 M sucrose, 2 mM PMSF, pH 7.4) (4). The buffer was removed and the monolayers were incubated for 2 min at room temperature with extraction buffer supplemented with 0.5% SDS, 10 mM N-ethylmaleimide, and protease inhibitors (200 μM leupeptin, 0.2 mg/ml α2-macroglobulin, 50 μg/ml apro tin, and 300 μM benzamidine). Cell lysates were removed from the tissue culture plates with an 18-gauge needle attached to a 5-ml syringe and boiled for 3 min. After cooling to room temperature, the lysates were passed three times through a 27-gauge needle to shear DNA released from lysed nuclei. For the plasma membrane in differentiated muscle cells (44), the cell suspension was then sonicated with a sonifier cell disruptor (model 350; Branson Sonic Power Co., Danbury, CT) with three sets of 10 1-s pulses at an output control of 2 and a 20% duty cycle (7). Nuclei and unbroken cells were removed by sedimentation at 500 g for 10 min at 4°C and the resulting postnuclear supernatant was adjusted to 0.075% BSA (added to reduce nonspecific binding of membranes to centrifuge tubes) ± 0.2 M NaCl. The postnuclear supernatant was then subjected to centrifugation at 100,000 g for 1 h at 4°C, fractionating it into a soluble supernatant (SI00) and a membrane pellet (PI00). In some cases, the PI00 fraction was further fractionated by flotation through a discontinuous sucrose gradient. The PI00 pellet was suspended to 2 ml with 50% wt/wt sucrose and dispersed by 10 strokes in a loose-fitting Dounce (Kontes Glass Co., Vineland, NJ) homogenizer. The fraction was then placed in a siliconized cellulose nitrate tube above 1 ml of 60% (wt/wt) sucrose and overlaid with 1.3 ml of 9% sucrose. All sucrose solutions contained 10 mM Tris, 10 mM N-ethylmaleimide, 0.075% BSA, and protease inhibitors and were adjusted to pH 8.6. The sucrose gradient was centrifuged in an SW60 rotor at 46,000 rpm (215,000 g at 37°C) for 16 h at 4°C. Material that accumulated at the 9%/50% sucrose interface (crude total membrane fraction) and at the bottom of the tube (large membrane-unassociated aggregates) was collected separately and diluted twice with 10 mM Tris containing 10 mM N-ethylmaleimide and protease inhibitors. For assay of RAPsyn or α subunit content, these fractions were brought to 0.5% Triton X-100 and 0.2% SDS, vortexed briefly, and incubated for 10 min on ice. The samples were then diluted with an equal volume of immunoprecipitation buffer (31) supplemented with 0.5% Triton X-100, 10 mM N-ethylmaleimide, and protease inhibitors before immunoprecipitation with either anti-RAPsyn serum or mAb61 as described above.

125I-a BTX Binding

125I-a BTX was prepared as previously described (30). Cell cultures were incubated in growth medium containing 2 nM 125I-a BTX for 6 h at 37°C. These prelabeled 125I-a BTX surface receptor complexes serve as a marker for the plasma membrane in differentiated muscle cells (44). Nonspecific binding was assessed in the presence of a 250-fold molar excess of unlabeled a BTX.

Peptide Mapping

RAPsyn immunoprecipitated from muscle and nonmuscle cell lines was analyzed by partial proteolytic digestion according to the procedure of Cleveland et al. (16, 17). Cells were metabolically labeled with [35S]methionine for 6 h, lysed, and immunoprecipitated with anti-RAPsyn serum. The immunoprecipitates were then resolved by SDS-PAGE and the portion of the dried gel containing RAPsyn was excised, rehydrated, and loaded into the lanes of a second polyacrylamide gel consisting of a 5% polyacrylamide stacking and 15% polyacrylamide resolving gel. Digestions were conducted within the stacking gel for 30 min at room temperature using 0.2 μg Staphylococcus aureus V8 protease (ICN Radiochemicals, Costa Mesa, CA) per sample. The resulting peptide fragments were separated by electrophoresis through the resolving gel and visualized by fluorography.

RNase Protection Assays

Total RNA was isolated by differential precipitation (15). Collected cells or tissues frozen rapidly in liquid nitrogen were homogenized (Tissumizer; Tekmar Co., Cincinnati, OH) in buffered 7.5 M guanidine hydrochloride, and RNA was precipitated with 0.7 vol of ethanol at −20°C. After centrifugation, the pellet was homogenized in 7.5 M guanidine solution and RNA was reprecipitated with 0.5 vol of ethanol. The RNA was reprecipitated a third time, resuspended in 3.75 M guanidine solution, and extracted with

The Journal of Cell Biology, Volume 108, 1989
phenol/chloroform (1:1). The RNA was then precipitated with 0.5 vol of ethanol and resuspended in 10% SDS. RNA was quantified by absorbance at 260 nm.

The RNase protection protocol was derived from a transcriptional mapping procedure provided by Promega Biotec (Madison, WI). A Pst I fragment of the mouse RAPsyn gene was subcloned into the transcription vector pBS (+) (Stratagene, San Diego, CA). This fragment contains parts of two exons of the mouse RAPsyn cDNA. A radiolabeled antisense probe was synthesized from plasmid linearized with Hind III. A typical 20 µl reaction contained 500 µCi each of unlabeled ATP, CTP, and GTP, 12 µM unlabeled UTP, 50 µCi of [α-32P]UTP (3000 Ci/mM), 0.5 µg of plasmid, and 8 U of T7 polymerase. The newly synthesized probe was extracted with phenol/chloroform (1:1), precipitated with 0.25 vol of 10 M ammonium acetate and 2.5 vol of ethanol and resuspended in hybridization buffer (80% formamide, 40 mM Pipes, pH 5.7, 0.4 M NaCl, and 1 mM EDTA) at 100,000 cpm/µl. Approximately 40% of the radiolabeled nucleotide was incorporated into RNA.

The RNA to be assayed (20 µg) was brought to 200 µl with diethylpyrocarbonate-treated water and precipitated with 50 µl of 10 M ammonium acetate and 625 µl of ethanol. The RNA was resuspended in 26 µl of hybridization buffer and 4 µl of probe was added. The hybridization mix was heated for 5 min at 80°C, briefly centrifuged, and incubated overnight in an inverted position at 45°C in a water bath. After hybridization, 300 µl of ice-cold RNase digestion buffer (10 mM Tris-HCl, pH 7.5, 5 mM EDTA, 300 mM NaCl) containing 40 µg/ml of RNase A (Sigma Chemical Co., St. Louis, MO) and 5 µg/ml of RNase T1 (Sigma Chemical Co.) was added and the digestion mixture was incubated for 60 min at room temperature. The mixture was incubated an additional 15 min at 37°C after the addition of 10 µl of 20% SDS and 50 µg of proteinase K (Sigma Chemical Co.). After one extraction with phenol/chloroform (1:1), the protected RNA was precipitated with 5 µg of carrier tRNA, 0.25 vol of 10 M ammonium acetate and 2.5 vol of ethanol. The precipitated RNA was washed well with 70% ethanol, dried, and resuspended in 5 µl of sample buffer (98% formamide, and 2.5 vol of ethanol) and resuspended in hybridization buffer (80% formamide, 40 mM Pipes, pH 6.7, 0.4 M NaCl, and 1 mM EDTA) at 100,000 cpm/µl. Approximately 40% of the radiolabeled nucleotide was incorporated into RNA.

The RNA to be assayed (20 µg) was brought to 200 µl with diethylpyrocarbonate-treated water and precipitated with 50 µl of 10 M ammonium acetate and 625 µl of ethanol. The RNA was resuspended in 26 µl of hybridization buffer and 4 µl of probe was added. The hybridization mix was heated for 5 min at 80°C, briefly centrifuged, and incubated overnight in an inverted position at 45°C in a water bath. After hybridization, 300 µl of ice-cold RNase digestion buffer (10 mM Tris-HCl, pH 7.5, 5 mM EDTA, 300 mM NaCl) containing 40 µg/ml of RNase A (Sigma Chemical Co., St. Louis, MO) and 5 µg/ml of RNase T1 (Sigma Chemical Co.) was added and the digestion mixture was incubated for 60 min at room temperature. The mixture was incubated an additional 15 min at 37°C after the addition of 10 µl of 20% SDS and 50 µg of proteinase K (Sigma Chemical Co.). After one extraction with phenol/chloroform (1:1), the protected RNA was precipitated with 5 µg of carrier tRNA, 0.25 vol of 10 M ammonium acetate and 2.5 vol of ethanol. The precipitated RNA was washed well with 70% ethanol, dried, and resuspended in 5 µl of sample buffer (98% formamide, 20 mM EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue). The sample was incubated at 95°C for 3 min and electrophoresed on a standard 40-cm 6% polyacrylamide/urea sequencing gel. The gel was then incubated in acetone/methanol (10% each) to remove the urea, dried, and exposed to Kodak XAR-5 film with an intensifying screen.

Results

Immunoprecipitation of RAPsyn from Metabolically Labeled Skeletal Muscle and Nonmuscle Cells

To examine whether nonmuscle rodent cells synthesize RAPsyn, various clonal cell lines were labeled with [35S]methionine and detergent lysates of these cells were immunoprecipitated with a rabbit antiserum raised against Torpedo RAPsyn. The monospecificity of this antiserum for RAPsyn and its use in immunoprecipitation of mouse RAPsyn from the muscle cell line BC3H1 have been described previously (31). When confluent cultures of the mouse fibroblast cell line L929 were incubated with [35S]methionine, lysed, and immunoprecipitated with the anti-RAPsyn serum, a prominent labeled species was obtained which migrates on SDS-PAGE as an ~43,000-Mr band (Fig. 1 A, lane 3). This species comigrates with authentic RAPsyn protein recovered from BC3H1 cells using an identical labeling/immunoprecipitation protocol (Fig. 1 A, lane 1). The anti-RAPsyn serum also recognized a protein of identical electrophoretic mobility from [35S]methionine-labeled MA-10 cells, a clonal line derived from a mouse Leydig cell tumor (Fig. 1 A, lane 6). Several lines of evidence indicate that the ~43,000-Mr species in L929 and MA-10 cells is recognized by the anti-RAPsyn serum in a specific manner: (a) it is not immunoprecipitated when normal rabbit serum (Fig. 1 A, lanes 5 and 8) or preimmune serum (not shown) is substituted for anti-RAPsyn serum; (b) it does not comigrate with actin or other major labeled proteins present in total L929 or MA-10 cell lysates (Fig. 1 A, lanes 9 and 10); and (c) its immunoprecipitation, as that of RAPsyn from BC3H1 cells, is blocked by an alkaline (pH 11) extract of Torpedo postsynaptic membranes by pH-11 extraction. (A) Immunoprecipitation of lysates from muscle BC3H1 cells (lanes 1 and 2), fibroblast L929 cells (lanes 3–5), or Leydig tumor MA-10 cells (lanes 6–8); total [35S]methionine-labeled protein from L929 (lane 9) or MA-10 (lane 10) cell lysates. (B) RAPsyn immunoprecipitated from BC3H1 cell lysates (lane 1); immunoprecipitation of lysates from mastocytoma P815 cells (lanes 2 and 3) or thymoma EL4 cells (lanes 4 and 5).

Figure 1. Specificity of immunoprecipitation of [35S]methionine-labeled 43,000-Mr proteins from muscle and nonmuscle cells. Various muscle and nonmuscle cells were labeled for 4 h with [35S]methionine and lysed as described under Materials and Methods before immunoprecipitation or total protein analysis. Equal aliquots of cell lysate were immunoprecipitated with either anti-RAPsyn serum (A, lanes 1–4, 6, and 7; B, lanes 1, 2, and 4) or normal rabbit serum (A, lanes 5 and 8; B, lanes 3 and 5). Anti-RAPsyn immunoprecipitations were performed in the absence (A, lanes 1, 3, and 6; B, lanes 1, 2, and 4) or presence (A, lanes 2, 4, and 7) of RAPsyn partially purified from AChR-rich Torpedo postsynaptic membranes by pH-11 extraction. (A) Immunoprecipitation of lysates from muscle BC3H1 cells (lanes 1 and 2), fibroblast L929 cells (lanes 3–5), or Leydig tumor MA-10 cells (lanes 6–8); total [35S]methionine-labeled protein from L929 (lane 9) or MA-10 (lane 10) cell lysates. (B) RAPsyn immunoprecipitated from BC3H1 cell lysates (lane 1); immunoprecipitation of lysates from mastocytoma P815 cells (lanes 2 and 3) or thymoma EL4 cells (lanes 4 and 5).
The 43,000-Mr band was found by immunoprecipitation with anti-RAPsyn serum. In contrast, no reliably detectable 43,000-Mr species can be immunoprecipitated from BC3H1 cells processed identically. 43,000-Mr protein as do BC3H1 cells processed identically. A10 cells, a smooth muscle line derived from Torpedo electric organ is its tight association with plasma membranes despite the fact that it is a peripheral rather than integral membrane protein (5, 32, 36). To examine whether RAPsyn is bound to membranes in nonmuscle cells as well, [35S]methionine-labeled 32, 36). To examine whether RAPsyn is bound to membranes in nonmuscle cells as well, [35S]methionine-labeled BMV in Nonmuscle Cells

To further investigate the synthesis of RAPsyn in nonmuscle cell types, we have used an RNase protection assay to detect and quantify RAPsyn and mRNA in cell lines. The probe used in the assay was a Pst I fragment of the mouse RAPsyn gene that we isolated using mouse RAPsyn cDNA clones (18; our unpublished results). This genomic probe encodes parts of two exons that, when used in the RNase protection assay, were predicted to protect fragments of 313 and 117 bp. A radiolabeled antisense probe derived from the genomic fragment was incubated with total mRNA prepared from L929 cells or differentiated C2 cells. Unhybridized RNA was then enzymatically digested and the protected fragments were analyzed by gel electrophoresis and fluorography. The C2 muscle cell mRNA yielded protected fragments of the predicted size whose intensity was proportional to the amount of C2 mRNA included in the assay (Fig. 3, lanes 1–3). Protected fragments of identical sizes were obtained with mRNA isolated L929 cells (Fig. 3, lane 4). The relative amount of RAPsyn mRNA present in the two cell lines was determined by quantifying the autoradiographic signals obtained; there was 5–10 times less RAPsyn mRNA in L929 cells than in C2 cells. Therefore, the combined results of the peptide mapping analysis and the RNase protection assay clearly demonstrate that the material recognized by the anti-RAPsyn serum in nonmuscle cells is indeed RAPsyn.

Association of RAPsyn Protein with Membranes in Nonmuscle Cells

One of the most intriguing properties of RAPsyn protein from skeletal muscle and from Torpedo electric organ is its tight association with plasma membranes despite the fact that it is a peripheral rather than integral membrane protein (5, 32, 36). To examine whether RAPsyn is bound to membranes in nonmuscle cells as well, [35S]methionine-labeled BMV in Nonmuscle Cells

To further investigate the synthesis of RAPsyn in nonmuscle cell types, we have used an RNase protection assay to detect and quantify RAPsyn and mRNA in cell lines. The probe used in the assay was a Pst I fragment of the mouse RAPsyn gene that we isolated using mouse RAPsyn cDNA clones (18; our unpublished results). This genomic probe encodes parts of two exons that, when used in the RNase protection assay, were predicted to protect fragments of 313 and 117 bp. A radiolabeled antisense probe derived from the genomic fragment was incubated with total mRNA prepared from L929 cells or differentiated C2 cells. Unhybridized RNA was then enzymatically digested and the protected fragments were analyzed by gel electrophoresis and fluorography. The C2 muscle cell mRNA yielded protected fragments of the predicted size whose intensity was proportional to the amount of C2 mRNA included in the assay (Fig. 3, lanes 1–3). Protected fragments of identical sizes were obtained with mRNA isolated L929 cells (Fig. 3, lane 4). The relative amount of RAPsyn mRNA present in the two cell lines was determined by quantifying the autoradiographic signals obtained; there was 5–10 times less RAPsyn mRNA in L929 cells than in C2 cells. Therefore, the combined results of the peptide mapping analysis and the RNase protection assay clearly demonstrate that the material recognized by the anti-RAPsyn serum in nonmuscle cells is indeed RAPsyn.
L929, MA-10, and BC3H1 cells were disrupted by sonication and fractionated into soluble (S100) and membrane-bound (P100) components. The S100 and P100 fractions as well as a sample of the initial postnuclear supernatant were solubilized and then immunoprecipitated with the anti-RAPsyn serum; the amount of RAPsyn recovered in the three fractions is compared in Table I. When BC3H1 cell sonicates were subjected to this procedure, 80-90% of the RAPsyn was recovered in the P100 fraction. This value is similar to that observed for both the AChR α subunit (98% in the P100 pellet), an integral membrane protein of BC3H1 cells, and surface-labeled 125I-α BTX (93% in the P100 pellet), a plasma membrane marker of differentiated BC3H1 cells. Upon further fractionation of the P100 fraction by flotation in a discontinuous sucrose gradient, virtually all (90-98%) of the RAPsyn, α subunit, and cell surface 125I-α BTX-AChR complexes were recovered in the total membrane fraction. Thus, RAPsyn present in the P100 fraction behaved as if it were truly membrane associated rather than in the form of an insoluble aggregate. When MA-10 and L929 cells were fractionated into P100 and S100, 75–85% of the immunoprecipitated RAPsyn was recovered in the P100 pellet, regardless of whether the salt concentration was kept low (10 mM Tris) or adjusted to 0.2 M NaCl immediately before centrifugation. In contrast, the major actin species present in MA-10, L929, and BC3H1 cell lysates was quantitatively recovered (≈95%) in the S100 fraction in all three cell types, as determined by SDS-PAGE analysis of total labeled proteins present in the postnuclear supernatant P100 and S100 fractions; therefore, soluble proteins partitioned efficiently into the supernatant. RAPsyn thus appears to be tightly membrane associated regardless of cell type, indicating that this association does not require the presence of muscle-specific proteins.

### Distribution of RAPsyn in Rodent Tissues

The presence of RAPsyn in MA-10 and L929 cells raised the question as to whether expression of RAPsyn is a property of certain transformed cell lines or whether it occurs in normal rodent cells as well. To address this issue, we prepared total mRNA from various mouse tissues and assayed for the presence of RAPsyn mRNA using the RNase protection assay described above (Fig. 4). As expected, a strong signal was obtained from mRNA prepared from mouse hindlimb (Fig. 4, lane 2), indicating the synthesis of significant quantities of RAPsyn in adult skeletal muscle (about threefold less than that present in the C2 mouse muscle cell line). Lesser amounts of RAPsyn-encoding mRNA were present in kidney (Fig. 4, lane 3), and in heart (lane 7; ≈15–25-fold less than that present in C2); the level of expression of RAPsyn in brain, liver, spleen, and uterus was below the limit of detection of the assay (<1/40 of that present in C2 cells); (lanes 3, 4, 6, and 8). The integrity of the mRNA isolated from the nonexpressing tissues was confirmed by Northern blot analysis with an actin probe (data not shown).

To determine if the RAPsyn mRNA present in nonmuscle tissues was actually translated, the synthesis of RAPsyn in cells derived from several tissues was examined. Cells were pulse labeled with [35S]methionine and assayed for RAPsyn synthesis by immunoprecipitation. Both mouse and rat cells were used since the anti-RAPsyn serum recognizes RAPsyn

---

**Table 1. Distribution of 35S-labeled RAPsyn among Subcellular Fractions Prepared from Muscle and Nonmuscle Cells**

| Cell line | Fraction | 35S-RAPsyn | 35S-actin | 35S-α | 125I-BTX |
|-----------|----------|-------------|-----------|-------|-----------|
|           | % of total | % of total | % of total | % of total | % of total |
| BC3H1     | S100     | 15          | 97        | 2     | 7         |
|           | P100     | 85          | 3         | 98    | 93        |
|           | 9%/50% sucrose | 95    | 96 | 90         |
| MA10      | S100     | 17          | 95        |       |           |
|           | P100     | 83          | 5         |       |           |
| L929      | S100     | 24          | 95        |       |           |
|           | P100     | 76          | 5         |       |           |

Association of RAPsyn with membranes in muscle and nonmuscle cells. BC3H1, MA-10, and L929 cells were labeled for 4 h with [35S]methionine and, in the case of BC3H1 cells, 2 nM 125I-α BTX. The cells were then rinsed, scraped, and broken by sonication. A postnuclear supernatant was prepared and fractionated into a crude membrane pellet (P100) and a soluble fraction (S100) by centrifugation for 1 h at 100,000 g. Between 80 and 100% of the RAPsyn protein, actin, α subunit, and 125I-BTX-labeled AChR present in the postnuclear supernatant was recovered in the S100 and P100 fractions. The P100 fraction from BC3H1 cells was further fractionated by flotation in a discontinuous sucrose gradient. Recovery of RAPsyn, α subunit, and bound 125I-BTX in the 9%/50% sucrose interface was 80–90% of that loaded onto the gradient, with the remainder distributed throughout the gradient. All values represent the average of at least two separate experiments.
Figure 4. Distribution of RAPsyn RNA expression in mouse tissues. Total RNA (20 μg) was isolated from differentiated C2 myotubes and mouse muscle, brain, liver, kidney, spleen, heart, and uterus, and assayed for RAPsyn mRNA by RNase protection. The protected fragments were analyzed by electrophoresis and fluorography. In all cases in which the 313-bp fragment was observed, the 117-bp fragment was also observed. Although the 117-bp fragment is not visible in the lane labeled Kidney, it is visible in a long exposure of the original x-ray film.

Figure 5. Synthesis of RAPsyn in other rodent cells. Monolayers of the rat hepatoma cell line H-4-II-E (lanes 7 and 8), primary cultures of embryonic rat heart cells (lanes 2–4), or skeletal muscle cells (lanes 5 and 6) were labeled with [35S]methionine for 4 h, lysed, and aliquots of cell lysate were immunoprecipitated with either anti-RAPsyn serum (lanes 2, 3, 5, and 7) or normal rabbit serum (lanes 4, 6, and 8). In lane 3, immunoprecipitation was performed in the absence of RAPsyn partially purified from AchR-rich Torpedo postsynaptic membranes by pH-11 extraction. (Lane 1) Positive control: RAPsyn immunoprecipitated from BC3H1 cells.

In all cases examined, we have found RAPsyn to be tightly membrane associated in both muscle and nonmuscle cells. Binding of RAPsyn to membranes therefore appears to be an intrinsic property of RAPsyn and is not dependent on the presence of AchR or other muscle-specific proteins. A similar conclusion had previously been drawn by Porter and Frohner from cell-free reconstitution studies demonstrating high affinity binding of isolated Torpedo RAPsyn to pure (protein-free) liposomes (36). The basis for the inherent lipophilicity of RAPsyn has not been established. Our recent finding that RAPsyn in mouse muscle BC3H1 cells is myristoylated (31) suggests, however, that RAPsyn may be anchored to the lipid bilayer via its myristate moiety, as are certain other peripheral membrane proteins (12, 37, 39). Consistent with this possibility is our finding that RAPsyn can be metabolically labeled with [3H]-myristate to the same extent in MA-10 and L929 cells as in BC3H1 cells (data not shown). Definitive proof of an essential role for myristate in the association of RAPsyn with membranes will, however, require both direct chemical identification of myristic acid with RAPsyn from nonmuscle cells and demonstration that abolishment of RAPsyn myristoylation by site-directed mutagenesis renders the protein incapable of associating with membranes.

The presence of RAPsyn in nonmuscle cells provides strong evidence that RAPsyn is synthesized by embryonic rat myotubes in primary culture (Fig. 5 B, lane 5). A specific signal was also obtained from 5-d-old cultures of embryonic rat cardiac myocytes, demonstrating the synthesis of RAPsyn in normal, untransformed cells of nonskeletal muscle origin (Fig. 5 B, lanes 2–4). In contrast, no 43,000-Mr, material was reliably immunoprecipitated from the rat hepatoma cell line H-4-II-E, indicating RAPsyn synthesis in these cells was below the limit detectable in the immunoprecipitation assay (<1/5 the RAPsyn produced by an equivalent number of L929 cells) (Fig. 5, lanes 7 and 8).

Discussion

Initially described as a component of Torpedo electric organ, RAPsyn (43K protein) was detected by immunostaining in vertebrate skeletal muscle nearly a decade ago (21). The distribution of RAPsyn in both tissues was found to be coextensive with postsynaptic clusters of AchRs (34, 42), suggesting that RAPsyn expression was restricted to AchR-containing cells of skeletal muscle origin. Here we provide immunological evidence, as well as evidence from peptide mapping and RNase protection studies, that RAPsyn is synthesized in certain cell types unrelated to skeletal muscle. This unexpected result raises interesting questions regarding the function of RAPsyn and its relationship with the AchR.
strong, albeit indirect, evidence that RAPsyn carries out some function other than or in addition to AChR clustering. One possibility is that RAPsyn is involved in other processes requiring the aggregation of proteins on the plasma membrane, such as receptor-mediated endocytosis (27) or cell surface antigen patching. In the latter instance, the lack of detectable RAPsyn synthesis in EL4 and P815 cells suggests that RAPsyn does not participate in cap formation in lymphoid cells. Alternatively, RAPsyn could function in a capacity not directly related to protein aggregation. In this regard it is of interest to note that RAPsyn from Torpedo electric organ has been reported to be an actin-binding protein (47) and a protein kinase (22), although evidence for either function in intact cells is lacking. Careful examination of whether RAPsyn codistributes with clustered plasma membrane proteins in nonmuscle cells might be useful in elucidating the role of RAPsyn in AChR-negative tissues.

There are several potential reasons why RAPsyn has not previously been described in nonmuscle cells. Using a two-site immunological assay, LaRochelle and Froehner detected RAPsyn in Torpedo electric organ and skeletal muscle but not in Torpedo liver, brain, spleen, or heart (25). These results differ from ours since we have found mouse heart to be positive for RAPsyn expression at both the mRNA and protein level. Although species differences cannot be ruled out, the most probable explanation for this discrepancy lies in the inability of the two-site assay to detect levels of RAPsyn <25% of that present in skeletal muscle (25). Since RAPsyn-encoding mRNA is 5-8-fold less abundant in mouse heart as in skeletal muscle, it is likely that the amount of RAPsyn present in Torpedo heart is below the limit of detection of the two-site ELISA. Low expression levels may also account for the lack of detection of RAPsyn in nonmuscle cells by immunofluorescence microscopy (5, 34). A more important factor may, however, be the localization of RAPsyn in nonmuscle cells: if the majority of RAPsyn is distributed along the membrane diffusely rather than focally (as on the postsynaptic membrane), it may not be concentrated enough to be visualized by immunofluorescence. A similar situation is likely to exist in undifferentiated skeletal muscle cells and prevent the detection of RAPsyn in these cells by light microscopy, despite our finding that RAPsyn expression is quantitatively and qualitatively similar in differentiated and undifferentiated muscle cells (19).

We thank Despina Ghement and Dr. Martin Matzuk for their help with tissue culture, Dr. Mario Ascoli for his permission to use the MA-10 cell line, and Drs. Chris Carr and Jonathan Cohen for Torpedo electric organ vesicles and anti-RAPsyn (43K) serum.

This research was supported with funds from the Senator Jacob Javits Center of Excellence in the Neurosciences and with grants from the National Institutes of Health, the Muscular Dystrophy Associations of America, and the Monsanto Company.

Received for publication 16 November 1988 and in revised form 28 December 1988.

References

1. Ascoli, M. 1981. Characterization of several clonal lines of cultured Leydig tumor cells: gonadotropin receptors and steroidogenic responses. Endocrinology. 108:88-95.

2. Barrantes, F. J., D.-Ch. Neugebauer, and H. P. Zingshem. 1980. Peptide extraction by alkaline treatment is accompanied by rearrangement of the membrane-bound acetylcholine receptor from Torpedo marmorata. FEBS (Fed. Eur. Biochem. Soc.) Lett. 112:73-78.

3. Bennett, M. R. 1983. Development of neuromuscular synapses. Physiol. Rev. 63:917-1048.

4. Ben-Ze'ev, A., A. Duerr, F. Solomon, and S. Penman. 1979. The outer boundary of the cytoskeleton: a lamina derived from plasma membrane proteins. Cell. 17:859-865.

5. Bloch, R. J., and S. C. Froehner. 1987. The relationship of the postsynaptic 43K protein to acetylcholine receptors in receptor clusters isolated from cultured rat myotubes. J. Cell Biol. 104:645-654.

6. Bloch, R. J., and W. G. Resnek. 1984. Isolation of acetylcholine receptor clusters in substrate-associated material from cultured rat myotubes using sperm. J. Cell Biol. 99:983-993.

7. Blount, P., and J. P. Merlie. 1988. Native forming of an acetylcholine receptor C subunit expressed in the absence of other receptor subunits. J. Biol. Chem. 263:1072-1080.

8. Bonner, W. M., and R. A. Laskey. 1974. A film detection method for tritium-labeled proteins and nucleic acids in polyacrylamide gels. Eur. J. Biochem. 46:83-88.

9. Buonomano, A., and J. P. Merlie. 1986. Transcriptional regulation of nicotinic acetylcholine receptor genes during muscle development. J. Biol. Chem. 261:16451-16458.

10. Burden, S. J. 1985. The subsynaptic 43-kDa protein is concentrated at developing nerve-muscle synapses in vitro. Proc. Natl. Acad. Sci. USA. 82:8270-8273.

11. Burden, S. J., R. L. DePalma, and G. S. Gottesman. 1983. Crosslinking of proteins in acetylcholine receptor-rich membranes: association between the C-subunit and the 43kD subsynaptic protein. Cell. 35:687-692.

12. Boss, J. E., and B. M. Selton. 1985. Myristic acid, a rare fatty acid, is the lipid attached to the transforming protein of Ross sarcoma virus and its cellular homolog. J. Virol. 53:7-12.

13. Carr, C., D. McCourt, and J. B. Cohen. 1987. The 43 kDa protein of Torpedo post-synaptic membranes: purification and determination of primary structure. Biochemistry. 26:7090-7102.

14. Cartaud, J., A. Sobel, A. Rousselet, P. F. Devaux, and J.-P. Changeux. 1981. Consequences of alkaline treatment for the ultrastructure of the acetylcholine-receptor rich-membranes from Torpedo marmorata electric organ. J. Cell Biol. 90:418-426.

15. Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, and W. J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:5294-5299.

16. Cleveland, D. 1983. Peptide mapping in one dimension by limited proteolysis of sodium dodecyl sulfate-solubilized proteins. Methods Enzymol. 96:222-229.

17. Cleveland, D., S. G. Fisher, M. W. Kirschner, and U. K. Laemmli. 1977. The relationship of the postsynaptic membrane proteins. J. Cell Biol. 75:622-629.

18. Cleveland, D., L. L. McLaughlin, J. Mudd, and J. P. Merlie. 1988. Identification of the mouse muscle 43,000 dalton acetylcholine receptor-associated protein (RAPsyn) by DNA cloning. J. Biol. Chem. 263:15602-15607.

19. Cleveland, D., L. S. Musil, A. Bonanno, and J. P. Merlie. 1989. Expression of RAPsyn (42K Protein) and nicotinic acetylcholine receptor genes is not coordinately regulated in mouse muscle. Neuron. 2:1077-1086.

20. Froehner, S. C. 1986. The role of the postsynaptic cytoskeleton in AChR organization. Trends Neurosci. 9:37-41.

21. Froehner, S. C., V. Guldbrandsen, C. Hymann, A. Y. Jeng, R. R. Neubig, and B. Cohen. 1981. Immunofluorescence localization at the mammalian neuromuscular junction of the Mr 43,000 protein of Torpedo post-synaptic membranes. Proc. Natl. Acad. Sci. USA. 78:5230-5234.

22. Gordon, A., and D. Milly. 1986. α, a Mr 43,000 component of post-synaptic membranes, is a protein kinase. Proc. Natl. Acad. Sci. USA. 83:4172-4174.

23. Kimes, B. W., and J. B. L. Brandt. 1976. Characterization of two putative smooth muscle cell lines from rat thoracic aorta. Exp. Cell Res. 98:349-366.

24. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London). 227:680-685.

25. LaRochelle, W. J., and S. C. Froehner. 1986. Determination of the tissue distributions and relative concentrations of the postsynaptic 43-kDa protein and the acetylcholine receptor in Torpedo. J. Biol. Chem. 261:5270-5274.

26. LaRochelle, W. J., and A. Catterall. 1981. Tetrodotoxin-insensitive sodium channels: binding of peptide neurotoxins in primary cultures of rat muscle cells. J. Biol. Chem. 256:6223-6229.

27. Maxfield, F. R., J. Schlessinger, Y. Shechter, I. Pastan, and M. C. Williamson. 1978. Collection of insulin, EGF, and α2 macroglobulin in the same patches on the surface of cultured fibroblast and common internalization. Cell. 14:805-810.

28. Merlie, J. P., and J. Lindstrom. 1983. Assembly in vivo of mouse muscle acetylcholine receptor: identification of an α subunit species that may be an assembly intermediate. J. Cell Biol. 94:747-757.

29. Merlie, J. P., and J. R. Sanes. 1986. Regulation of synapse-specific genes. In Molecular Aspects of Neurobiology. R. L. Montalcini, P. Calissano, E. R. Kandel, and A. Maggi, editors. Springer-Verlag GmbH & Co., Heidelberg, Federal Republic of Germany, 75-80.

30. Merlie, J. P., and R. Sebba. 1981. Acetylcholine receptor subunits tran...
sit a precursor pool before acquiring α-bungarotoxin binding activity. J. Biol. Chem. 256:3605-3608.

31. Musil, L. S., C. Carr, J. B. Cohen, and J. P. Merlie. 1988. Acetylcholine receptor-associated 43K protein contains covalently bound myristate. J. Cell Biol. 107:1113-1121.

32. Neubig, R. R., E. K. Krodel, N. D. Boyd, and J. B. Cohen. 1979. Acetylcholine and local anesthetic binding to Torpedo nicotinic postsynaptic membranes after removal of nonreceptor peptides. Proc. Natl. Acad. Sci. USA. 76:690-694.

33. Nghiem, H.-O., J. Cartaud, C. Dubreuil, C. Kordeli, G. Buttin, and J.-P. Changeux. 1983. Production and characterization of a monoclonal antibody directed against the 43,000-dalton polypeptide from Torpedo marmorata electric organ. Proc. Natl. Acad. Sci. USA. 80:6403-6407.

34. Peng, H. B., and S. C. Froehner. 1985. Association of the postsynaptic 43K protein with newly formed acetylcholine receptor clusters in cultured muscle cells. J. Cell Biol. 100:1698-1705.

35. Porter, S., and S. C. Froehner. 1983. Characterization and localization of the Mr=43,000 proteins associated with acetylcholine receptor-rich membranes. J. Biol. Chem. 258:10034-10040.

36. Porter, S., and S. C. Froehner. 1985. Interaction of the 43K protein with components of Torpedo postsynaptic membranes. Biochemistry. 24:425-432.

37. Rein, A., M. R. McClure, N. R. Rice, R. B. Luftig, and A. M. Schwartz. 1986. Myristoylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc. Natl. Acad. Sci. USA. 83:7246-7250.

38. Reznikoff, C., D. Brankow, and C. Heidelberger. 1973. Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. Cancer Res. 33:3231-3238.

39. Rhee, S. S., and E. Hunter. 1987. Myristoylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J. Virol. 61:1045-1053.

40. Rousselet, A., J. Cartaud, P. F. Devaux, and J.-P. Changeux. 1982. The rotational diffusion of the acetylcholine receptor in Torpedo marmorata membrane fragments studied with a spin-labelled α-toxin: importance of the 43000 protein(s). EMBO (Eur. Mol. Biol. Org.) J. 1:439-445.

41. Schubert, D., A. J. Harris, C. E. Devine, and S. Heinemann. 1974. Characterization of a unique muscle cell. J. Cell Biol. 61:398-413.

42. Sealock, R., B. E. Wray, and S. C. Froehner. 1984. Ultrastructural localization of the Mr 43,000 protein and the acetylcholine receptor in Torpedo postsynaptic membranes using monoclonal antibodies. J. Cell Biol. 98:2239-2244.

43. Simpson, P., and S. Savion. 1982. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells: cross striations, ultrastructure, and chronotropic response to isoproterenol. Circ. Res. 50:101-116.

44. Smith, M. M., J. Lindstrom, and J. P. Merlie. 1987. Formation of the α-bungarotoxin binding site and assembly of the nicotinic acetylcholine receptor subunits occur in the endoplasmic reticulum. J. Biol. Chem. 262:4367-4376.

45. Sobel, A., T. Heidmann, J. Hoffler, and J.-P. Changeux. 1978. Distinct protein components from Torpedo marmorata membranes carry the acetylcholine receptor site and the binding site for local anesthetics and histriionicotoxin. Proc. Natl. Acad. Sci. USA. 75:510-514.

46. Tzartos, S. J., D. E. Rand, B. L. Einarson, and J. M. Lindstrom. 1981. Mapping of surface structures of Electrophorus acetylcholine receptor using monoclonal antibodies. J. Biol. Chem. 256:8635-8645.

47. Walker, J. H., C. M. Boustead, and V. Witzeman. 1984. The 43-K protein, α, associated with acetylcholine receptor containing membrane fragments is an actin-binding protein. EMBO (Eur. Mol. Biol. Org.) J. 3:2287-2290.

48. Yaffe, D., and O. Saxel. 1977. Serial passage and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature (Lond.). 270:725-727.